CAT-179 / Catamaran Bio - LARVOL DELTA

Spinner Flask Modelling of Wave-Style Bioreactors Enables Suspension-Phase Cell Culture Process Development of Allogeneic CAR-NK Cell Therapies (ASGCT 2023) - "Two distinct CAR-NK products, CAT-179 and CAT-248, were produced in three different culture systems: 150mL spinner flasks, 1L static cultures and 2L wave-style bioreactors. Use of the model revealed that the optimization of this parameter is critical to maximizing the yield of potent drug products in the CAT-248 process.¶In summary, our data demonstrates proof of concept for the use of spinner flasks for culturing NK cells, providing a small-scale platform to model a wave-style suspension culture process more accurately. Use of this model will expedite scale-up process development as we pursue our clinical goals, shortening the path to clinical readiness and supplying a more complete data package in support of the clinical manufacturing of multiplex-engineered NK cells for solid tumor applications."

Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice (AACR 2023) - "Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor • HER-2 • IL15 • TGFB1

Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) - "Catamaran Bio, Inc...announced new data demonstrating preclinical pharmacology and in vivo efficacy from the Company’s two CAR-NK cell therapies in solid tumors have been selected for poster presentations during the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL....'These advances are part of our continuing progress toward the clinic and lay the foundation for our first in-human studies in solid tumors to begin in 2024'....Demonstration that CAT-248 significantly reduces growth of 786-O renal cell carcinoma xenografts in both intraperitoneal and subcutaneous in vivo models....Demonstration that a single dose of TAILWIND^®-engineered CAR-NK cells induces durable regression in multiple HER2 xenograft models."

New trial • Preclinical • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors (SITC 2022) - "CAT-179 effectively reduced SKOV-3-luc tumor burden in NSG mice (95% AUC, p<0.0001 for survival). Conclusions CAT-179 is a promising demonstration of the Catamaran CAR-NK platform, as a novel off-the-shelf cell therapy to overcome the challenges associated with solid tumors."

Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor • HER-2 • IFNG • IL15 • TNFA

Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting (Businesswire) - "Data from a second CAR-NK cell therapy construct engineered using the TAILWIND™ platform are presented in a poster...Highlights include...CAT-179 demonstrated HER2-CAR-driven interferon gamma (IFNγ) production and tumor cell killing in vitro when co-cultured with HER2+ tumor cells; CAT-179 was resistant to TGFβ-mediated immunosuppression in vitro, indicating that the cells will be protected from TGFβ-mediated immune suppression in the tumor microenvironment; Engineering of IL15 in CAT-179 significantly enhanced NK cell persistence and in vitro and in vivo and eliminated the need for exogenous cytokine support; CAT-179 showed potent anti-tumor activity in vivo against a xenografted HER2+ N87 gastric cancer cell line and led to a significant survival benefit in tumor-bearing mice."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR‑NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting (Businesswire) - "Catamaran Bio, Inc...announced that the company will present preclinical efficacy data for its allogeneic, cryopreserved CAR-NK cell therapies designed to treat solid tumors, engineered using Catamaran’s TAILWIND^TM platform. The data demonstrate the promise of two of the company’s CAR-NK cell therapies, CAT-248 and CAT-179, for the treatment of solid tumors, and will be presented in two poster presentations at the Society for Immunotherapy in Cancer (SITC) 37th Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Allogeneic Natural Killer cells engineered to express HER2 CAR, Interleukin 15 and TGF beta dominant negative receptor effectively control HER2+ tumors (AACR 2022) - "Moreover, CAT-179 administration to NSG mice showed expansion and persistence of the transferred cell product. CAT-179 addresses key hurdles to allogeneic cell therapy for solid tumors and is a promising new therapeutic approach for HER2 expressing breast, gastric and other tumors."

Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor • HER-2 • IL15 • TGFB1

Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT‑179, a HER2-targeted Allogeneic CAR-NK Cell Therapy (Businesswire) - "CAT-179 demonstrated HER2-CAR-driven interferon gamma production and tumor cell killing in vitro when co-cultured with HER2+ tumor cells. The TGFβ DNR in CAT-179 demonstrated resistance to TGFb-mediated immunosuppression in vitro. CAT-179 cells persisted in vitro without the need for exogenous cytokines and showed significantly enhanced in vivo persistence up to at least 40 days in mouse models. CAT-179 showed potent anti-tumor activity against a xenografted HER2+ ovarian cancer cell line (SKOV3), leading to a substantial survival benefit in tumor-bearing mice. Overall, CAT-179 treated animals demonstrated tumor reduction of 98% compared to control animals (p<0.019 two-tailed t-test) and had a median survival of 114 days vs. control animal median survival of 60 days."

Preclinical • Oncology • Solid Tumor

Catamaran Bio to Present Preclinical Efficacy Data on Allogeneic Solid Tumor CAR-NK Program at AACR Annual Meeting 2022 (Businesswire) - "Catamaran Bio...announced that the company will present preclinical efficacy data for its CAT-179 program, an allogeneic solid tumor CAR-NK cell therapy, at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held in New Orleans, Louisiana, April 8-13, 2022. CAT-179 is an allogeneic, cryopreserved HER2-targeted CAR-NK cell therapy engineered using Catamaran’s TAILWIND platform."

Preclinical • Oncology • Solid Tumor

Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021 (Businesswire) - "Catamaran’s CAR-NK programs include CAT-179 targeting HER2-expressing breast and gastric cancers, and CAT-248 targeting CD70-expressing cancers....Catamaran Bio...today announced that it has designated CAT-179, a HER2-targeted CAR-NK cell therapy, and CAT-248, a CD70-targeted CAR-NK cell therapy, as its first preclinical development programs. The company also announced that data supporting the CAT-248 program will be presented during a poster session at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in person in Atlanta from December 11-14, 2021."

Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor